Abstract
Resected brain metastases have a high rate of local recurrence without adjuvant therapy. Adjuvant whole-brain radiotherapy (WBRT) remains the standard of care with a local control rate >90 %. However, WBRT is delivered over 10–15 days, which can delay other therapy and is associated with acute and long-term toxicities. Permanent brachytherapy implants can be used at the time of surgical resection, which both provides necessary adjuvant therapy as well as allowing the patient’s disease to be treated fully in one visit. Several radioisotopes have been used in central nervous system brachytherapy, including low dose rate Iodine-125 and Cesium-131. Cesium-131 in particular provides an excellent balance between optimizing local control and minimizing toxicities associated with radiation treatment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Petr MJ, McPherson CM, Breneman JC, et al. Management of newly diagnosed single brain metastasis with surgical resection and permanent I-125 seeds without upfront whole brain radiotherapy. J Neurooncol. 2009;92:393–400.
Ruge MI, Suchorska B, Maarouf M, et al. Stereotactic 125iodine brachytherapy for the treatment of singular brain metastases: closing a gap? Neurosurgery. 2011;68:1209–18. Discussion 1218–1209.
Ruge MI, Kickingereder P, Grau S, et al. Stereotactic biopsy combined with stereotactic (125)iodine brachytherapy for diagnosis and treatment of locally recurrent single brain metastases. J Neurooncol. 2011;105:109–18.
Wernicke AG, et al. Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases. J Neurosurg. 2014;121:338–48.
Wernicke AG, Smith AW, Taube S, Yondorf M, Trichter S, Nedialkova L, Sabbas A, Christos P, Ramakrishna R, Pannullo S, Stieg P, Schwartz T. Cesium-131 brachytherapy for recurrent brain metastases offers durable salvage treatment for previously irradiated patients. J Neurosurg. 2016;1–8 [Epub ahead of print].
Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol. 2013;31:65–72.
Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037–44.
Molenaar R, Wiggenraad R, Verbeek-de Kanter A, et al. Relationship between volume, dose and local control in stereotactic radiosurgery of brain metastasis. Br J Neurosurg. 2009;23:170–8.
Sneed PK, Mendez J, Vemer-van den Hoek JG, et al. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg. 2015;123:373–86.
Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291–8.
Yang R, Wang J, Zhang H. Dosimetric study of Cs-131, I-125, and Pd-103 seeds for permanent prostate brachytherapy. Cancer Biother Radiopharm. 2009;24:701–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Wernicke, A.G., Taube, S., Smith, A.W., Parashar, B. (2017). Central Nervous System Brachytherapy. In: Mayadev, J., Benedict, S., Kamrava, M. (eds) Handbook of Image-Guided Brachytherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-44827-5_18
Download citation
DOI: https://doi.org/10.1007/978-3-319-44827-5_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-44825-1
Online ISBN: 978-3-319-44827-5
eBook Packages: MedicineMedicine (R0)